The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge-Reference-Cited by-同舟云学术

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge

Published:2019-04 Issue:8 Volume:64 Page:499-503
ISSN:2095-9273
Container-title:Science Bulletin
language:en
Short-container-title:Science Bulletin

Author:

Zhang Yi-Chen,Zhou Qing,Chen Zhi-Hong,Zhang Ming-Feng,Yang Jin-Ji,Tu Hai-Yan,Zhang Xu-Chao,Xu Chong-Rui,Yan Hong-Hong,Peng Xiao-Xiao,Bai Xiao-Yan,Chuai Shao-Kun,Ye Jun-Yi,Wu Yi-Long

Funder

Guangdong Science and Technology Department

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference12 articles.

1. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

2. Phase I/II study of AC0010, mutant-selective EGFR inhibitor, in non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation;Wu;J Thorac Oncol,2017

3. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study;Papadimitrakopoulou;Ann Oncol,2018

4. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients;Yang;Clin Cancer Res,2018

5. AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients;Xu;Mol Cancer Ther,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allelic Context of EGFR C797X–Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes;Journal of Thoracic Oncology;2023-11

2. Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR ‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance;Respirology Case Reports;2022-10-17

3. Research on cancer treatment methods based on clone gene evolution;4TH INTERNATIONAL CONFERENCE ON FRONTIERS OF BIOLOGICAL SCIENCES AND ENGINEERING (FBSE 2021);2022

4. A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study;Clinical Cancer Research;2021-11-05

5. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report;Annals of Palliative Medicine;2021-07